drugset / Trial / NCT05590637

Comparing Antipsychotic Medications in LBD Over Time

NCT05590637

RandomizedParallel-groupOpen-labelTreatment

Summary

The primary objective of this study is to determine whether treatment with pimavanserin or quetiapine is associated with a greater improvement in psychosis when used in a routine clinical setting to treat hallucinations and/or delusions due to Parkinson's disease (PD) or dementia with Lewy bodies (DLB) - collectively referred to as Lewy body disease (LBD).

Timeline

Start
2022-04-22
Primary completion
2026-08
Completion
2027-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Pimavanserin Small molecule
Comparator Quetiapine Small molecule